CATALYST BIOSCIENCES INC (CBIO) Stock Price, Quote, News and Overview
NASDAQ:CBIO - Nasdaq - US14888D2080 - Common Stock - Currency: USD
CBIO Quote, Performance and Key Statistics
0.5113
-0.01 (-2.65%)
The current stock price of CBIO is 0.5113 USD. In the past month the price increased by 4.37%. In the past year, price decreased by -8.37%.
CBIO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CBIO
Company Profile
Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 7 full-time employees. The company went IPO on 2006-04-12. The firm is focused on the development and commercialization of Hydronidone for the treatment of nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease in the United States. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a spectrum of chronic liver diseases. A Phase 1 clinical trial of Hydronidone has been completed in the United States and generated pharmacokinetic (PK), safety and tolerability data of single and multiple ascending doses of Hydronidone in United States healthy subjects. Hydronidone is a structural analogue of the approved anti-fibrotic (pulmonary fibrosis) drug pirfenidone. Hydronidone has been shown to inhibit both p38y kinase activity and TGF-b1- induced excessive collagen synthesis in vitro in hepatic stellate cells (HSCs), which are recognized as critical events in the development and progression of fibrosis in the liver.
Company Info
CATALYST BIOSCIENCES INC
611 Gateway Blvd Ste 710
South San Francisco CALIFORNIA 94080 US
CEO: Nassim Usman
Employees: 7
Company Website: https://www.catalystbiosciences.com/
Phone: 16508710761.0
CATALYST BIOSCIENCES INC / CBIO FAQ
What is the stock price of CATALYST BIOSCIENCES INC today?
The current stock price of CBIO is 0.5113 USD. The price decreased by -2.65% in the last trading session.
What is the ticker symbol for CATALYST BIOSCIENCES INC stock?
The exchange symbol of CATALYST BIOSCIENCES INC is CBIO and it is listed on the Nasdaq exchange.
On which exchange is CBIO stock listed?
CBIO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CATALYST BIOSCIENCES INC stock?
6 analysts have analysed CBIO and the average price target is 16.32 USD. This implies a price increase of 3091.86% is expected in the next year compared to the current price of 0.5113. Check the CATALYST BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CATALYST BIOSCIENCES INC worth?
CATALYST BIOSCIENCES INC (CBIO) has a market capitalization of 19.42M USD. This makes CBIO a Nano Cap stock.
How many employees does CATALYST BIOSCIENCES INC have?
CATALYST BIOSCIENCES INC (CBIO) currently has 7 employees.
What are the support and resistance levels for CATALYST BIOSCIENCES INC (CBIO) stock?
CATALYST BIOSCIENCES INC (CBIO) has a support level at 0.5 and a resistance level at 0.53. Check the full technical report for a detailed analysis of CBIO support and resistance levels.
Is CATALYST BIOSCIENCES INC (CBIO) expected to grow?
The Revenue of CATALYST BIOSCIENCES INC (CBIO) is expected to decline by -100% in the next year. Check the estimates tab for more information on the CBIO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CATALYST BIOSCIENCES INC (CBIO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CBIO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CBIO, evaluating the profitability, health, valuation and growth aspects
- CATALYST BIOSCIENCES INC (CBIO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CATALYST BIOSCIENCES INC (CBIO) Sales and EPS estimates to see what analysts future expectations are.
- CATALYST BIOSCIENCES INC (CBIO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CATALYST BIOSCIENCES INC (CBIO) Insider and Institutional Ownership to learn about the owners and their transactions.
- CATALYST BIOSCIENCES INC (CBIO) Stock Chart to make your own analysis
- CATALYST BIOSCIENCES INC (CBIO) Latest news and press-releases to stay up to date.
Does CATALYST BIOSCIENCES INC (CBIO) stock pay dividends?
CBIO does not pay a dividend.
When does CATALYST BIOSCIENCES INC (CBIO) report earnings?
CATALYST BIOSCIENCES INC (CBIO) will report earnings on 2024-03-28, after the market close.
What is the Price/Earnings (PE) ratio of CATALYST BIOSCIENCES INC (CBIO)?
CATALYST BIOSCIENCES INC (CBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.37).
CBIO Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CBIO. When comparing the yearly performance of all stocks, CBIO is one of the better performing stocks in the market, outperforming 93.94% of all stocks.
CBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CBIO. The financial health of CBIO is average, but there are quite some concerns on its profitability.
CBIO Financial Highlights
Over the last trailing twelve months CBIO reported a non-GAAP Earnings per Share(EPS) of -1.37. The EPS decreased by -465.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -444.02% | ||
| ROE | -1257.95% | ||
| Debt/Equity | 0 |
CBIO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to CBIO. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of -117.39% and a revenue growth -100% for CBIO